Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer to work with Warf to examine stem cells

Pfizer to work with Warf to examine stem cells

6th May 2009

Pfizer will work with the Wisconsin Alumni Research Foundation (Warf) to discover how new medicines may be able to improve the way stem cells restore damaged tissue.

Dr Ruth McKernan, chief scientific officer of the company’s regenerative medicine division, made this comment after it was announced the firm had signed a licence allowing it to use the body’s human embryonic stem cell patents to develop new drugs.

She explained the agreement with Warf will provide the materials and information to work on a range of treatments.

“Pfizer’s stem cell research and development goal is three-fold – to use human cells as tools in our drug discovery efforts, to improve the safety of new treatments and most importantly to move towards cell therapy,” Dr McKernan commented.

The work to discover and advance medications for some debilitating diseases could provide the public with huge benefits, she concluded.

Earlier this week, Pfizer announced Dr Freda Lewis-Hall had been appointed as its new chief medical officer and senior vice-president.

Jeffrey B Kindler, chairman and chief executive officer of the business, stated her achievements and experience would fit into the firm’s goals to improve world health.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.